SCHEMBL6181040

SCHEMBL6181040

C[C@H](COc1ccc(N)cc1)N(C)C

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 5/20 0.52
TSHR P16473 2/20 0.50
ALDH1A1 P00352 3/20 0.42
MAPT P10636 2/20 0.42
KDM4E B2RXH2 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
MAPK1 P28482 1/20 0.40
TOP1 P11387 1/20 0.40
GAA P10253 1/20 0.40
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
APP P05067 1/20 0.40
CYP3A4 P08684 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL188875 1.00 TDP1 (0.52) TDP1TSHRALDH1A1MAPTKDM4E
SCHEMBL24352850 0.85 KMT2A (0.45) MAPK1RAB9A
SCHEMBL24352739 0.85 KMT2A (0.45) MAPK1RAB9A
SCHEMBL17563248 0.82 USP2 (0.45) TSHRMAPTKDM4ENPSR1TOP1
SCHEMBL3857517 0.81 TDP1 (0.52) TDP1TSHRALDH1A1MAPTKDM4E
SCHEMBL19533014 0.80 LMNA (0.59) TDP1TSHRALDH1A1KDM4ENPSR1
SCHEMBL14407437 0.79 TDP1 (0.59) TDP1TSHRALDH1A1MAPTMAPK1
SCHEMBL109648 0.79 TDP1 (0.64) TDP1TSHRALDH1A1MAPTKDM4E
SCHEMBL25336536 0.79 CYP3A4 (0.56) TSHRALDH1A1MAPTTOP1MAOB
SCHEMBL25320768 0.79 CYP3A4 (0.56) TSHRALDH1A1MAPTTOP1MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1507530-B1 DIAMINOTHIAZOLES AND USE THEREOF AS CDK4 INHIBITORS HOFFMANN LA ROCHE (CH) 2005-11-02 EP disclosed
EP-1507530-A1 DIAMINOTHIAZOLES F. HOFFMANN-LA ROCHE AG (CH) 2005-02-23 EP disclosed
US-6818663-B2 AS INHIBITORS OF CYCLIN-DEPENDENT KINASE 4 (CDK4); ANTIPROLIFERATIVE AGENTS; FOR THERAPY OF CANCER, TUMORS HOFFMANN-LA ROCHES 2004-11-16 US disclosed
US-20040006058-A1 DIAMINOTHIAZOLES CHU XIN-JIE (US) 2004-01-08 US disclosed
WO-2003097048-A1 DIAMINOTHIAZOLES F. HOFFMANN-LA ROCHE AG (CH) 2003-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006058-A1 DIAMINOTHIAZOLES CDK4, CDK1, CDK2 TDP1 1402/4885TSHR 2383/4885ALDH1A1 1361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.